Validating rnai targets
Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.The specificity of this regulation is achieved by partial sequence complementarity between the mi RNA and its target m RNA.Understanding which m RNAs are targeted by each particular micro RNA is critical to an understanding of the biologic role of any particular mi RNA.The only way to be completely certain that a protein is instrumental in a given disease is to test that idea in humans.Obviously, scientists cannot use human clinical trials in the early phases of drug development; therefore, a potential target protein must undergo a validation process.
Thanks in large part to the Human Genome Project and the dramatic drop in the cost of DNA sequencing, scientists can sort through the roughly 35,000 genes in the human genome to identify sites linked to disease.In addition, we describe a rigorously controlled strategy for determining the bona fide mi RNA binding sites in the 3′UTR of m RNAs.(read more) #wp-subscribe.wp-subscribe-1 #wp-subscribe.wp-subscribe-1 h4 #wp-subscribe.wp-subscribe-1 p #wp-subscribe.wp-subscribe-1 .regular-text #wp-subscribe.wp-subscribe-1 .submit #wp-subscribe.wp-subscribe-1 .thanks #wp-subscribe.wp-subscribe-1 .error #wp-subscribe.wp-subscribe-1 .Researchers must sift through vast amounts of data in search of proteins that could be instrumental in human disease — too many potential leads to evaluate one at a time.
At NCATS, the goal is to prioritize targets based on how likely they are to lead to a promising therapeutic.learn More that are applied in drug discovery and development. Bio Xcel, Center of Excellence (Co E) for Research and Development is an innovation hub focused on the development of transformative patient treatments.